The Money Value of Time

Date: 2026-09-12

Author: Wealth & Means Staff

Source: https://wealthandmeans.com/essay/the-money-value-of-time

There's a moment when something becomes true, and a later moment when the world finally acts on it, and we spend almost all our attention on the first one. Which is strange, because the second is where people actually live. Everything worth arguing about has a lag built into it — the interval between a fact existing and anybody being able to see it, price it, or act on it. That interval isn't a rounding error. It's frequently the entire investment, the entire career, the entire political crisis. Two opposite errors grow in that gap, and this week produced both. There's the market that refuses to price a thing until it's been proven, which is why four out of five dealers in the world's largest electric-car market turn away a perfectly healthy vehicle nobody can inspect. And there's the market that prices the destination on day one, which is why incumbents get declared obsolete roughly thirty years before their customers agree to leave. Steam power reached commercial service in 1807 and steam-powered ships are still running today — two centuries of cash flow the obituary writers missed. In The Greater Debate, two men argue about whether a government can freeze the price of bread and slowly discover they're arguing about time instead. And in Let's Invent Again, a country doctor notices that the gap between a good medicine and a working medicine is, in fact, the whole business. Knowing what wins is the easy half. The hard half is knowing how long, and who's standing in between.

TL;DR

Episode 49 examines the lag between when something becomes true and when institutions, markets, or customers finally act on it. Semaglutide may reduce respiratory flare-ups for reasons medicine has not yet explained; China's used-EV market discounts batteries it cannot reliably inspect; Copart is buying vehicle-condition data rather than merely another auction channel; and Hungary's bonds offer a convergence trade whose payoff depends on political time. The week ahead centers on a potentially hiking Federal Reserve, Bank of Japan, and Bank of England, plus two public listings built on difficult-to-check models. The Knowledge Bomb explains why disruption often strengthens incumbents before it replaces them. The Greater Debate tests Nixon-era price controls against market clearing, and William Upjohn's friable pill shows that delivery can matter as much as discovery.

Key Takeaways

Welcome to Wealth and Means — advice dressed up like hard work.

Good day to our members in Australia, Austria, Canada, Costa Rica, France, Germany, Hong Kong, India, Israel, Singapore, Taiwan, the United Kingdom and the United States. Episode forty-nine. Let's get into it.

Here's the thread running through today's show. There's a moment when something becomes true, and there's a later moment when the world finally acts on it, and those two moments are almost never the same day. Sometimes they're decades apart. A drug has been quietly protecting people's lungs for years before anyone measures it. A technology is declared dead about thirty years before its customers agree. A country's bonds still pay you for a risk that's already been retired everywhere except in the spreadsheet. We're very good at arguing about what's true. We're terrible at pricing how long it takes.

So in What You Didn't See in the News, we've got a weight-loss drug doing something surprising to asthma, a used-car market that's set an expiry date on electric vehicles, a one point nine billion dollar deal where the cars are the least interesting part, a bond desk making a nineteen-nineties trade in twenty twenty-six, a small port in Yemen that just changed hands, a Shanghai molecule that's now a London company's problem, a tiny American clock maker having the best quarter of its life, a Chinese tutoring company that found profit in the strangest place, a newsletter company that turns out to be a major podcast payer, and a set of teeth from Sulawesi that just rewrote the timeline of human pharmacology.

Then Wake Up Ready has a genuinely unusual week ahead — a Fed meeting where the market's pricing the opposite of what it was pricing in the spring, two central banks moving the day after, and two Nasdaq listings on the same Friday that are both, in their own way, a bet on a model nobody can check. Our Knowledge Bomb is about why steamships didn't kill sailing ships and what that has to do with the software in your company's stack. Humor Me takes the economic moat literally, which turns out to be funnier than it should be. The Greater Debate puts J. Howard Pew across from Richard Nixon on whether a government can freeze the price of bread. And in Let's Invent Again, a doctor in Michigan who noticed that the pills he was prescribing were passing straight through his patients.

Every story today sits in the gap between when a thing becomes true and when anybody does something about it. That gap has a length. Almost nobody prices the length.

Let's go.

Each week we explore ideas that help you pause, reflect, and think more deeply about the opportunities all around you.

It's the perfect mix — a little information, a few stats, some real-world insights, and just enough deep talk to make you feel smarter before your second cup of coffee. A quick thank-you to our sponsor — AgentWeekly.ai - chronicling the absurd, the ambitious, and the algorithmically-challenged corners of the AI agent economy.

WHAT YOU DIDN'T SEE IN THE NEWS

We'll start with a drug doing something nobody prescribed it for. Researchers pulled United Kingdom medical records and found that people on semaglutide — that's the molecule inside Ozempic and Wegovy — had nearly forty percent fewer asthma attacks than a comparable group. About twenty percent fewer COPD flare-ups, too. The work came out of Imperial College London's National Heart and Lung Institute, led by Chloe Bloom, presented by Doctor Bohee Lee at the European Respiratory Society Congress in Barcelona. Each arm of the study followed somewhere between twenty thousand and twenty-two thousand patients, compared against people who'd started an older diabetes drug called a sulfonylurea. Here's the part that makes it interesting rather than just nice. The other drugs in the same GLP-one class didn't show it. Not at any dose, not at any baseline severity. So this isn't a category effect where anything that helps you lose weight helps you breathe. Something more specific is going on, and nobody's fully explained it yet. Chronic lung disease is a managed condition — you don't cure it, you keep it from flaring, and every avoided flare is an avoided emergency room visit. If a metabolic drug starts moving a respiratory number that reliably, the line between two medical specialties gets redrawn, and so does every formulary and prior-authorization rule built on top of that line. Bloom herself put the brake on it, and she's right to: nobody should start one of these for their lungs. The finding was always true. It just took somebody assembling twenty thousand records to make it visible.

The benefit existed for years. It became real the week somebody measured it.

That same gap — between what's true and what's provable — is currently destroying a lot of value in China. Rest of World reported this week that about four out of five used-car dealers in China now refuse to take an all-electric vehicle older than five years. Not because those cars are broken. Because nobody can tell whether they're broken. A three-year-old electric car in China resells for roughly forty-five percent of its original price, down from almost fifty-five percent in twenty twenty-three, according to the China Automobile Dealers Association. China has forty-four million electric vehicles on its roads, which makes it the first country on earth where these things are aging in bulk. And the most expensive component, the battery, has no agreed standard for measuring its health. The maddening part is that it's measurable. Every modern electric car can report battery condition through a diagnostic port, and third-party services will certify the reading. Dealers mostly don't ask. They price on age, mileage, remaining warranty and model reputation — four things that tell you almost nothing about the actual chemistry. Fleet telematics firm Geotab looked at twenty-two thousand of these cars and found the average one loses just over two percent of capacity a year. Fast-charge it hard and that roughly doubles. Chinese manufacturers exported more than two and a half million electric vehicles last year, twice the prior year, and Chinese cars are now fifty-five percent of electric sales in countries outside Europe and the United States. Every one of those markets inherits the same unanswered question, on a five-year delay. Somebody's going to build the battery credit bureau, and that business will be worth more than several of the carmakers.

The car isn't depreciating. The uncertainty is.

Which is more or less why a salvage auction company just spent nearly two billion dollars on a company that doesn't sell wrecks. On Wednesday evening, Copart agreed to acquire ACV Auctions for ten dollars and fifty cents a share in cash, a deal worth about one point nine billion dollars — about a forty-five percent premium to where ACV was trading before the news leaked. ACV runs dealer-to-dealer wholesale auctions for perfectly drivable used cars, which is a different business from Copart's, and the market reaction told you something: ACV jumped more than forty-four percent in a single session on a hundred and sixteen million shares, thirty-five times its normal volume. The thing Copart is actually buying isn't the auction. It's the inspection. ACV's whole model is built on sending someone to physically assess a car and produce a standardized condition report, including audio recordings of the engine — a condition report a dealer four states away will trust enough to bid against. That's the asset. Copart spent decades becoming the place where insurers dispose of total losses, a market where condition barely matters because the car is already written off. Buying ACV moves it into the market where condition is the entire question. Structurally, this is a bet that the scarce thing in used vehicles isn't inventory or logistics — it's a verified description. Which, as we just discussed, is exactly the thing the electric transition is making harder. Copart's funding it entirely from cash on hand, with no financing condition, which is its own quiet statement about who has balance sheet right now.

They didn't buy a marketplace. They bought a trusted opinion.

Now to a bond desk making a trade that hasn't been available in about thirty years. Bloomberg reported Thursday that Schroders has been buying Hungarian government debt as a bet on eventual euro adoption. James Ringer, who runs an unconstrained bond mandate there, calls Hungarian bonds the single best sovereign trade in the world right now, and he's holding both the hard-currency and the local forint paper. If you weren't trading in the late nineteen-nineties, the convergence trade needs explaining. When a country credibly commits to joining the euro, its bond yields have to fall toward German and French levels, because the currency risk that justified the extra yield is going away. You get paid for the gap closing. Hungary's own debt management agency said this week that long forint yields are only about halfway through that decline and could fall another hundred and fifty to two hundred and fifty basis points toward roughly four percent. The reason this is a story about measurement is that nothing has actually happened yet. Hungary hasn't joined anything. There's no date. What's changed is the perceived probability, following the political reset in Budapest earlier this year — and a probability is precisely the thing a bond market is bad at pricing smoothly. It tends to sit still and then move all at once. The uncomfortable half of the trade is that convergence bets are famously unforgiving if the political commitment wobbles, and Hungary's debt-to-output ratio is heading toward seventy-seven and a half percent. You're not being paid for the economics. You're being paid for the uncertainty about the politics.

The yield is the market admitting it doesn't know yet.

Speaking of things the market prices badly, a small port changed hands in Yemen on Wednesday. Houthi forces took Mokha, on the Red Sea coast, and according to multiple Yemeni government sources, followed it the next day by taking Perim Island. Mokha is not a large commercial port. It sits about seventy-five kilometres north of the Bab el-Mandeb strait, which is the narrow gate between the Red Sea and the Gulf of Aden, and which roughly twelve percent of world trade passes through. Perim Island sits in the strait itself. Here's the geography that matters. You don't need to control a chokepoint to control what happens at a chokepoint. You need a position beside it — somewhere to keep boats, radar, and people, close enough to reach shipping lanes and far enough from the obvious target list. Mokha and Perim together give exactly that. Nobody has attacked anything yet. That's the point. The value of the position is that it doesn't have to be used to change what an underwriter charges, and war-risk insurance premiums move on capability, not on incidents. So the first thing that reprices isn't oil, it's the cost of sending a hull through that water, and after that, the routing decisions of every carrier weighing the Suez versus going around Africa, which adds roughly ten days. This landed on a Wednesday and a Thursday, in the middle of a week when nobody in markets was looking at Yemen, and that's usually when leverage gets accumulated cheaply.

Leverage isn't at the chokepoint. It's next door, being quiet.

Another kind of leverage changed hands earlier in the month, in oncology. HUTCHMED, which is a Chinese pharmaceutical company, licensed a cancer drug called HMPL-A eight-thirty to GSK for a hundred and ten million dollars up front, with milestones that could take the total to one point two nine five billion dollars, plus royalties. GSK gets worldwide rights excluding mainland China, Hong Kong, Macau and Taiwan. HUTCHMED keeps those. The molecule itself is genuinely novel — it's what's called an antibody-targeted therapy conjugate, where a small-molecule KRAS inhibitor gets bolted onto an antibody that seeks out EGFR, so the toxic part is delivered to the tumour rather than to the patient generally. Early targets are colorectal, pancreatic and lung cancer. Now think about which direction that deal runs. For thirty years the standard arrangement was that Western pharma discovered molecules and licensed them into Asia. This is the opposite: discovery in Shanghai, commercialization in London, with the originator paying nothing and keeping its home market. Roughly a third of large pharma's recent in-licensing has come from Chinese biotech, and the reason is unglamorous — trials run faster and cheaper there, so the same money buys more evidence. What GSK is actually paying a hundred and ten million dollars for is a package of measurements it would have taken longer and cost more to generate itself. The global phase one program starts in the second half of this year, which is the moment the number stops being theoretical.

The invention happened in one country. The proof is what crossed the border.

There's a company on the Nasdaq almost nobody watches whose entire business is measurement, and it just had the best quarter in its history. Frequency Electronics — ticker F-E-I-M — reported Thursday after the close and the stock closed up forty-two point four percent the next day. Record revenue of twenty-three and a half million dollars, up seventy percent year over year and fifty-two percent sequentially. Funded backlog at a record one hundred twenty-nine million dollars, up eighty-two percent. Gross margin expanded to about forty-six percent, operating margin cleared twenty-two percent, and operating income went from four hundred thousand dollars a year ago to five point two million. What they make is precision time. Atomic clocks and frequency standards for satellites, navigation payloads and electronic warfare systems — the reference signal that everything else measures itself against. Here's why the backlog jumped. Every serious defence program right now is working on positioning and navigation that survives without GPS, because GPS jamming has gone from exotic to routine. A satellite constellation or a missile that can't get a signal has to carry its own sense of time, precisely enough to navigate on physics alone. That requirement was a niche for forty years and is now a line item in a lot of budgets. Management said they're increasingly confident of a hundred and fifty million dollars or more in annual revenue by fiscal twenty twenty-nine. A backlog up eighty-two percent is a customer base telling you, in advance and in writing, that they've stopped trusting the signal they used to trust.

When the reference you borrowed stops working, you start paying for your own.

A very different kind of reset happened at a Chinese education company this week. Seventeen Education and Technology Group — ticker Y-Q — reported second quarter results and posted its first profit, on either accounting basis, since it was forced to reinvent itself. Revenue was up two hundred fifty-four point six percent. Operating loss margin went from negative one hundred twelve percent a year ago to negative zero point seven percent. Net income margin came in at positive one point two percent, against negative one hundred two percent. First-half net loss shrank to eighteen point three million renminbi from fifty-six point nine million. The board also authorized a buyback of up to ten million dollars starting September third. To appreciate this you have to remember what happened to this sector. Beijing's twenty twenty-one crackdown on for-profit tutoring erased tens of billions of dollars of market value more or less overnight, and most of these companies became slow-motion liquidations. Seventeen Education survived by selling classroom software to schools, which is a low-margin government-adjacent business. What flipped the number was a consumer AI membership product — personalized agents for teachers, students and district administrators — sold as a subscription rather than as tooling. So the revenue that saved the company came from the side of the desk that was supposed to be off-limits. That's worth watching well beyond China, because the regulatory question about tutoring was always about tutors, and this is a product that doesn't employ any.

Regulate a business model and it comes back wearing different clothes.

Here's one that reorders the podcast industry league table without anyone announcing it. On Friday, Substack launched a dedicated podcast tab inside its app, and in the process told Podnews something the audio business hadn't really absorbed: creators publishing podcasts on Substack collectively earn over two hundred million dollars a year on the platform. That's a newsletter company. It has no ad network to speak of, no dynamic insertion, no measurement standard, no upfront presentation. It quietly built a payment rail for audio that's now larger than most of the networks that will be shaking hands in New York this week. Substack also put out download numbers for a new show, Organizing Things, which pulled ten thousand three hundred eighty-five downloads in its first week with, in their words, no paid promotion and no ad spend. Read the fine print though — co-host Shea Serrano is a five-time New York Times bestseller who came from Amazon and Wondery, and he arrived with a hundred and twenty-eight thousand existing newsletter subscribers. So the story isn't organic discovery. It's that an audience you already own converts across formats almost frictionlessly, which is a different and far more valuable claim. The whole advertising apparatus of podcasting exists to solve attribution — proving that an ad worked. Subscriptions skip the problem entirely, because the payment is the proof.

Two hundred million dollars a year, and not one of those dollars needed an attribution model.

And finally, the oldest story on the list by about twenty-five thousand years. In Science Advances on Wednesday, a team working on the Indonesian island of Sulawesi reported that two sets of prehistoric human remains carry chemical traces of arecoline — the psychoactive compound in betel nut — locked into the teeth. One of the individuals dates to somewhere between sixteen thousand and twenty-five thousand years ago. That pushes the earliest firm evidence of habitual human drug use back by at least three thousand years, and it puts it well before agriculture. The evidence is what makes this a measurement story rather than an archaeology story. The teeth carry a distinctive wear pattern, grooves consistent with repeatedly sucking on a hard round object one to two centimetres across, and those grooves have presumably been sitting in collections and in the ground for a very long time. What changed is that residue analysis got sensitive enough to pull an identifiable compound out of dental calculus and name it. Professor Adam Brumm's team didn't find new behaviour. They found a way to read behaviour that was already there. People have been managing their own neurochemistry since the last ice age, which reframes every argument about whether that's a modern affliction, and it should also make you wonder what else is sitting in museum drawers waiting for an instrument that hasn't been invented yet.

The habit is twenty-five thousand years old. The ability to see it is about a week old.

And that's the pattern across all ten of those. Let's carry it forward into the week ahead, because the calendar has a genuinely strange one for us.

WAKE UP READY

Start with Wednesday, because Wednesday is the whole week. At two in the afternoon Eastern, the Federal Open Market Committee closes a two-day meeting and announces a rate decision, and the market is positioned for something it wasn't positioned for six months ago. As of midweek, futures were pricing roughly sixty-two to sixty-nine percent odds of a twenty-five basis point hike, and zero percent — zero — odds of a cut. The current target range is three and a half to three and three-quarters percent. So forget the cut narrative entirely. The thing to listen for isn't whether they move, it's the justification. If the statement frames a hike as pre-emptive insurance against inflation expectations drifting, that's a Fed that thinks it's ahead of the problem. If it frames it as a response to realized demand, that's a Fed that thinks it's behind. Second-order: the first reading pressures long duration and steepens the curve, and the second one hits rate-sensitive equities and anything financed with floating debt — regional bank loan books, commercial real estate refinancings, and the private credit funds holding them.

Nobody spent this year preparing for a hiking Fed. That's exactly why it hurts.

That same morning, eight-thirty Eastern, we get August advance retail sales. Everyone will quote the headline number, which is mostly autos and gasoline and mostly noise. The number that matters is the control group — the piece that feeds directly into output calculations, stripping out autos, gas, building materials and food service. Consensus has the consumer soft but not breaking. The tell is whether any strength is concentrated in a handful of categories or spread across them. Second-order: if the control group misses, watch small-cap consumer discretionary first, because that's where the leverage to purely domestic spending sits and it reprices before anything else does. And notice the sequencing — the data lands five and a half hours before the decision, which means the committee has it and you'll get to watch whether they acknowledge it.

Two releases, one morning. One of them tells you what the other one already knew.

Thursday, it goes global. The Bank of Japan concludes a meeting with its policy rate at zero point seven five percent, the highest it's been since nineteen ninety-five, and markets are pricing around sixty-two percent odds of another twenty-five basis point hike. The Governor has said publicly that a hike is on the table at every meeting, which is central-bank language for stop asking. Watch the yen, not the statement. A hiking Bank of Japan alongside a hiking Federal Reserve is a very different setup from a hiking Bank of Japan alone, because the carry trade math depends on the differential, not the level. Second-order: if the differential narrows faster than expected, capital that's been parked overseas by Japanese institutions starts coming home, and that's a bid disappearing from long-dated debt in Europe and the United States — the marginal buyer of everybody else's duration deciding to buy his own.

Japan's been financing the world quietly for thirty years. Thirty years is not forever.

Same day, the Bank of England. Bank Rate sits at three point seven five percent, and a Reuters poll had fifty-six of sixty-four economists expecting no change through year-end, so a hold is thoroughly priced. Don't watch the decision, watch the vote split. Three members of the Monetary Policy Committee already voted for a hike on the thirtieth of July, and the thing that keeps that alive is services inflation, which is the stickiest component and the one most tied to wages. A four-to-five split reads as a hold. A six-to-three split reads as a hike that's been postponed. Markets are pricing a quarter point by the end of this year and two more in twenty twenty-seven. Second-order: the gilt curve is the transmission channel here, and it feeds mortgage pricing with about a six-week lag, so a hawkish split this Thursday shows up in British household budgets around Halloween.

The decision is the headline. The count is the news.

Then Friday brings two listings that belong in the same sentence even though they're in different industries. Holtec Nuclear prices on the Nasdaq under ticker H-N-U-C — fifty million shares at fifteen to eighteen dollars, up to nine hundred million dollars raised, at a valuation of as much as ten and two-tenths billion dollars, with JP Morgan and Guggenheim leading a book that also has Goldman, Citi and BofA on it. Holtec is the Camden, New Jersey company recommissioning the Palisades plant in Michigan — which would be the first American commercial reactor ever to restart after a permanent shutdown — and it plans a dual-unit small modular reactor project there of about six hundred eighty megawatts, targeting operation in the early twenty-thirties. It generated two hundred sixty-nine point nine million dollars of revenue in the first half of this year at a forty-three point nine percent gross operating margin. At the midpoint, you're paying about forty-one times pro forma earnings. Now, the same day, on the same exchange, Orion one-eighty Insurance Group prices under ticker O-I-G — twenty million shares at fifteen to seventeen dollars, up to three hundred forty million dollars, at around one and six-tenths billion dollars. It's a Melbourne, Florida specialty homeowners and flood insurer, the second largest excess and surplus lines homeowners writer in the country by direct written premium, roughly six hundred one million dollars of managed premium over the trailing year across fourteen states, and it swung to thirteen and a half million dollars of net income on eighty point one million of revenue in the first half, from a three million dollar loss a year earlier. Founder Kenneth Gregg keeps control through Class B shares.

A reactor company and a hurricane insurer, same exchange, same Friday. Someone at Nasdaq has a sense of humour.

Here's why they're one story. Both are asking you to underwrite a model of something that hasn't happened yet. Holtec's valuation rests on small modular reactors that won't generate a watt commercially until the next decade, priced off a licensing and construction timeline. Orion one-eighty's rests on catastrophe models for Florida wind and flood, in a state where the last few years have repeatedly embarrassed the models. Neither one can hand you a verified outcome. They can only hand you a methodology. Second-order: if both price at the top of the range, that's a market with a high tolerance for model risk right now, and you'll see it show up immediately in the pipeline behind them — every specialty insurer and every advanced-energy developer sitting on a confidential filing moves up their timeline. If one prices wide, you learn which kind of unverifiable risk investors are currently willing to fund.

Two prospectuses, two different unknowables, one afternoon of price discovery.

One more, and it's not a data release. Monday through Friday, the podcast industry relocates to Terminal Five in New York — the Sounds Profitable Business Summit on Monday and Tuesday, the I-A-B Upfronts on Wednesday, and Podcast Movement proper on Thursday and Friday. This is the first time the flagship has been in New York, which is a deliberate signal to the ad-buying side of the business. And the reason to care, if you don't make podcasts, is that audio is the last large medium without a settled measurement standard, which is exactly why its advertising rates behave so strangely.

An entire industry flying to one building to argue about how to count.

So here's my watch-for. Thursday at eleven-thirty in the morning, Tom Webster presents the fourth edition of The Podcast Landscape at the Sounds Profitable Business Summit, and he's already said publicly that it's going to cause — his word — consternation. When a researcher pre-announces that his own data is going to upset the room, the data is usually about audience size or audience age, and either one reprices a lot of ad inventory. I'd rather watch that than the Fed presser, and I'll tell you why: the Fed is going to tell you what it thinks. A number that embarrasses an industry tells you what's actually true.

And that is how you wake up ready.

KNOWLEDGE BOMB

A technology can lose the future long before it loses its customers.

Steam power entered scheduled commercial service in the United States in eighteen-oh-seven. More than two centuries later, steam-powered ships are still operating in American waters.

The microprocessor arrived in nineteen seventy-one. But it didn't instantly eliminate the room-sized computers built from transistors, circuit boards and vacuum tubes that came before it. And even today, some of the world's largest banks still rely on mainframes and software written in COBOL.

New technologies arrive quickly.

Replacement happens slowly.

Investors repeatedly confuse three separate events. First, a new technology becomes possible. Second, customers begin experimenting with it. Third, the old technology becomes economically obsolete. Those events can be separated by years — or decades.

Steamships didn't immediately kill sailing ships. In fact, competition from steam helped produce some of the fastest and most efficient sailing ships ever built. The incumbent improved because it had to.

The same pattern appeared in computing. Vacuum tubes gave way to transistors. Transistors gave way to integrated circuits. Integrated circuits gave way to the microprocessor. But each transition required more than a superior component. Businesses had to replace equipment, rewrite software, redesign workflows, retrain employees, and accept the risk that the new system might fail.

That brings us to the supposed SaaS apocalypse.

The bear case says generative AI will destroy traditional software in two ways. One: AI makes each employee more productive, so companies need fewer software seats. Two: AI-generated code lets businesses build their own applications instead of paying monthly subscriptions.

Both risks are real. But neither proves that established software disappears tomorrow.

Anyone may soon be able to generate something that looks like a customer-management system. That doesn't answer who maintains it, secures it, integrates it, audits it, and keeps it running for the next ten years. In enterprise software, the difficult part is rarely producing the first version of the code. The difficult part is becoming the trusted place where the company's data, permissions, workflows and institutional memory live.

This doesn't mean every SaaS company is safe. Thin software products — simple interfaces with little proprietary data, weak customer attachment, and functions that AI can easily reproduce — may face real extinction. Seat-based pricing may also weaken. If ten employees become five employees supervising five AI agents, selling ten identical licenses stops making sense.

But the likely transition isn't that all software revenue goes to zero. It's that software companies change what they charge for. Instead of charging per human seat, they may charge per automated action, transaction, workflow, unit of consumption, or measurable result. The winners may earn more by completing the work. The losers will keep charging customers merely to access another dashboard.

So here's the practical investor checklist. When the market declares that an incumbent is obsolete, ask five questions.

One: is this a system of record, or merely a convenient interface? The system holding the customer's critical data is harder to replace.

Two: what would migration actually require? Count the integrations, retraining, compliance reviews, security risks and potential downtime — not just the subscription fee.

Three: can the incumbent add the new technology itself? An established company with customers, data and distribution may be better positioned to deploy AI than the startup trying to displace it.

Four: is the business model dying, or merely changing? Falling seat counts may lead to consumption or outcome-based pricing rather than disappearing revenue.

Five: what does the valuation already assume? A durable company can be a bad investment if its price assumes permanent dominance. A declining company can be a good investment if the market assumes immediate extinction and the decline takes twenty years.

That last distinction matters. Technology analysis asks: what eventually wins? Investment analysis asks: how long will the transition take, what happens to cash flow along the way, and what expectations are already in the stock price?

The lesson from steamships, mainframes and enterprise software isn't that disruption is fake. It's that disruption has a clock.

Markets often price the final destination on the first day of the journey. But customers move more slowly, because they've got infrastructure, contracts, habits, regulations and careers tied to the existing system.

The most dangerous incumbents are the ones pretending nothing has changed. The most interesting investments may be the ones that recognize the change, possess the distribution to absorb it, and have enough time to reinvent themselves.

Today's Knowledge Bomb. Don't ask only whether a technology will be replaced. Ask what must happen before the customer can safely replace it — and how many years of cash flow exist between now and then.

HUMOR ME

There's a particular kind of reverence in finance for the economic moat. We treat it like sacred architecture. Warren Buffett says a great business needs one, and suddenly every earnings call starts sounding like a briefing from the Hundred Years' War.

Analysts will nod solemnly while a CEO talks about widening the moat, as if the company just ordered another shipment of alligators and is currently debating the depreciation schedule on boiling tar. "S-G-and-A came in a little elevated this quarter due to routine drawbridge maintenance and an unseasonal spike in reptile feed." Nobody laughs. They just update their models.

If we took the metaphor all the way, the Q-and-A would get even better. "We're seeing a two-ton battering ram advancing on the enterprise sales gate. Are you responding with standard archers, or should we bake heavy-crossbow CapEx into next quarter?" And the CEO, completely straight-faced: "Our current parapet height still provides adequate coverage against light infantry. We've also locked in multi-year oil contracts out of the Levant to protect against pitch shortages."

Brand loyalty becomes serfs swearing fealty because leaving the castle means starvation in the wilderness. Network effects turn into a Roman phalanx — individually fragile, but lock ten thousand users shield-to-shield and nobody gets out without being trampled. Disruptive innovation is just trebuchets. Your carefully planned five-year roadmap is irrelevant the moment a two-hundred-pound limestone boulder arrives from three hundred yards away.

The quiet truth is that most moats don't get stormed. They get ignored. The real threat tunnels under with offshore contractors, or simply sells to the peasants outside the walls for ninety percent less. History's full of fortresses that looked impregnable until somebody floated over them in a hot-air balloon dropping leaflets that said the old product was finished.

So the next time a company brags about its economic moat, remember: every castle eventually becomes an algae-choked municipal liability. You can spend billions fortifying the perimeter. Somebody always invents gunpowder. And the market, as usual, prices that in faster than the drawbridge can close.

GREATER DEBATE

There's an old rule about dinner parties. If you want to know whether the room is full of comfortable theorists or scarred practitioners, bring up the price of bread during a crisis. It's time for the Greater Debate. Because one side says a price is information, the other says a price is where the social contract catches fire, and suddenly everybody at the table is extremely interested in the bread basket.

The house lights are down. Two oak lecterns under warm tungsten. No slides, no moderator, no tasteful bowl of water pretending this is going to stay civilized. History's waived chronology tonight so our witnesses can examine the full record.

The question sounds simple. Can a sovereign state legitimately freeze prices to protect its people from inflation — or does market control eventually destroy the very stability it promises to defend?

Stage right, J. Howard Pew, longtime president of Sun Oil and an uncompromising defender of competitive enterprise. He measured economic claims in barrels, pipelines, payrolls, and whether the machinery actually ran.

Stage left, Richard Milhous Nixon, thirty-seventh president of the United States, who on the fifteenth of August, nineteen seventy-one imposed a ninety-day national freeze on wages and prices. Public reaction was strongly positive. Inflation moderated through the first phases. The Nixon Presidential Library records both the administration's intent to administer economic shock treatment and its promise that the freeze would be temporary.

Pew reaches the microphone first. He doesn't open with theory.

"A price isn't a favor granted by a merchant. It isn't a privilege issued by Washington. It's information."

He lets that sit.

"When the price of beef rises, that number carries two instructions at once. Consumers should economize. Producers should supply more. And it reaches the shopper, the rancher, the trucker, the butcher, the lender and the feed supplier without waiting for any of them to agree with each other. Freeze that number below its market level and both instructions disappear. Demand stays high, because the product looks cheap. Supply weakens, because producing it stops being worth the trouble."

He turns slightly.

"You can preserve the number printed on the label. You cannot order the product to stay behind it."

Nixon takes that without visible irritation.

"That's how prices work in ordinary times. A president earns his salary in the other kind."

He steps out from behind the lectern.

"Inflation becomes a coordination crisis. Workers demand higher wages because they expect prices to rise. Businesses raise prices because they expect wages and materials to cost more. Lenders demand protection. Suppliers shorten contracts. Everybody tries to move first, because moving second means absorbing the loss. Each of those decisions is rational. Together they're a spiral."

"A temporary freeze interrupts that race. It tells labor and industry that neither side gets punished for standing still while the other one charges ahead. It buys time for fiscal and monetary policy to work."

He pauses.

"The freeze isn't the cure. It's the operating table the cure gets attempted on. You don't ask a surgeon to repair an artery while the patient is sprinting through the parking lot."

Restrained laughter, then a murmur of agreement.

Pew doesn't wait for it to finish.

"The difficulty isn't that your officials might pick the wrong price. It's that there is no single correct price for them to pick. A national ceiling has to somehow account for efficient factories and inefficient ones. Nearby suppliers and distant ones. New inventory and old. Changing quality, seasonal demand, transport interruptions, credit costs — thousands of local conditions known only to the people standing in front of them. So the bureaucracy starts granting exemptions. And then companies stop competing for customers and start competing for favorable rulings. Lawyers replace salesmen at the margin. Political access becomes a form of capital."

"And your temporary program develops a survival instinct. Once you fix the price of the finished product, you have to investigate the price of its inputs. Then the inputs to those inputs. The state doesn't set out to manage the whole economy. It arrives there one reasonable exception at a time."

Nixon straightens.

"Then let's discuss the thing market theory treats rather casually. Who receives the scarce goods."

Silence. Not empty this time — tight.

"A market-clearing price doesn't distribute bread according to hunger. Or heating oil according to cold. Or medicine according to illness. It distributes according to purchasing power. In a national emergency, letting prices rise until the poorest citizens withdraw from the queue may clear the market beautifully. It may also be politically and morally intolerable."

"Controls paired with rationing can ask the affluent to surrender some consumption so essential goods stay available to everyone. In war or embargo, the state already decides where steel, fuel, shipping and labor have to go. Pretending the highest bidder always represents the highest national purpose isn't neutrality. It's government by auction."

That one visibly rattles the room.

Pew doesn't dismiss it. He lets the silence settle before he answers.

"A market price does ration by money. Unequal wealth means unequal sacrifice. I concede that. But suppressing the price doesn't abolish rationing. It changes the currency. Instead of money, people pay in waiting time, personal connections, deteriorating quality, side payments, political influence, or simple luck. The wealthy still find supply. The poor stand in the official queue."

Then he lands the harder blow.

"Mr. President — if controls are merely a bridge to sound policy, what happens when the government builds the bridge and refuses to reach the opposite bank? You restrained the visible prices while pursuing policies meant to stimulate demand. When the controls loosened, the accumulated increases reappeared, into food shortages and an oil shock. By September of nineteen seventy-four, consumer inflation had reached twelve percent, and the economy was entering a deep recession. The Bureau of Labor Statistics documents both the early moderation and the later surge."

He doesn't raise his voice for the last line.

"You didn't eliminate inflation, Mr. President. You made part of it wait backstage."

The room goes completely still.

Nixon doesn't get defensive. He acknowledges the trap.

"Controls are politically easier to impose than to remove. That's true. The freeze creates winners who demand its continuation, losers who demand exemptions, and officials who believe one more adjustment will finally make the machinery run properly. Lift the ceilings and the delayed increases arrive together, which makes the release look like proof that more control was needed. A temporary intervention becomes a government's alibi for avoiding monetary restraint, fiscal discipline, or a politically painful reduction in demand."

But he won't surrender the emergency case.

"If a short freeze is enacted openly, alongside credible monetary and fiscal correction, and ended on a published schedule, it buys social cooperation that orthodox policy alone may never command. Governments don't operate only through incentives. They operate through legitimacy. A technically correct policy the public can't endure may never survive long enough to become effective."

Pew accepts the force of it. And then he does something the room doesn't expect. He concedes his own weakness.

"Markets communicate scarcity quickly. They don't guarantee that frightened societies will accept the message. A sudden shock can drive food, fuel or housing beyond the reach of millions before any new supply has a chance to arrive. Telling those people that today's suffering will inspire tomorrow's investment is economically coherent and politically combustible. A free economy can be lost if its defenders look indifferent to the human interval between the shock and the adjustment."

Both men are quiet now, under the lights.

Here's what actually happened in that room. It stopped being an argument about prices somewhere in the middle and became an argument about time. Pew was asking what produces goods next month and next year. Nixon was asking what holds the country together tonight. Those aren't the same question, and neither man was answering the other one.

Pew's fear is that political relief silences the signals recovery depends on. Nixon's fear is that preserving those signals without cushioning the blow destroys public consent before recovery can begin.

So maybe the real distinction isn't between action and inaction. It's between a control used as a clock and a control used as a curtain. A clock buys a defined interval in which the government confronts the actual shortage, the excess demand, the fiscal imbalance, the monetary instability. A curtain just hides the damage and invites the audience to applaud the scenery.

And here's where it lands on you. The state can command the number. The market still determines the consequence. But a society is more than a market, and consequences arrive at different speeds for different people — which is exactly why the price of bread is never just the price of bread.

And that… is The Greater Debate.

LET'S INVENT AGAIN

In the late nineteenth century, medicine was often a gamble dressed up as science.

Patients swallowed powders that tasted foul, clumped unevenly and delivered inconsistent doses. When pills appeared, they promised convenience but frequently failed the only test that mattered: they didn't dissolve. The hard outer shell resisted the stomach's acids, and many simply passed through the body intact, carrying their payload unused. Doctors prescribed with hope more than certainty. Patients swallowed and waited. Results varied wildly.

And here's the cruel part. The doctor had no way to tell which failure he was looking at. If the patient didn't improve, was that the wrong diagnosis, the wrong drug, the wrong dose — or a pill that never opened? Four completely different problems, all producing exactly the same observation.

Into this imperfect system stepped William Upjohn, a physician from rural Michigan who refused to accept that the delivery of medicine should stay so unreliable.

Born in eighteen fifty-three in Richland, Upjohn practiced in an era when the tools of his trade lagged behind the knowledge. He saw the gap daily. Powders were messy and imprecise. Existing pills were rigid and stubborn. The prevailing assumption was that a solid form was progress enough. Upjohn disagreed. Around eighteen eighty he began experimenting with a different kind of pill — one soft enough that a thumb could crush it, yet stable enough to survive handling and shipping. He called the quality friability. The idea was simple and radical at once: the pill should break down readily in the stomach so the active ingredients could actually reach the bloodstream. He wasn't inventing new chemistry. He was solving the last-mile problem of absorption.

The technical challenge was manufacturing. Hand-rolled or crudely pressed pills varied in size, hardness and dose. Consistency was nearly impossible at any scale. In eighteen eighty-four Upjohn devised a machine that could produce friable pills at a regulated dosage. The device compressed the mixture just enough to hold its shape without creating the impermeable shell that had defeated earlier versions. Suddenly a doctor could trust that one pill matched the next. Patients received predictable amounts of medicine. The uncertainty that had plagued oral therapy began to shrink. He patented the pill itself the following year — United States patent number three hundred twelve thousand forty-one.

Two years after the machine, he founded the Upjohn Pill and Granule Company.

But he still had a product whose great virtue was completely invisible. You can't look at two pills and tell which one will dissolve. So Upjohn made the invisible thing testable, and then he mailed the test. He sent thousands of physicians a small pine board, a sample of a competitor's hard pill, and a sample of his own, and invited them to try hammering each one into the wood. The rival drove into the pine like a nail. His crumbled. Doctors ran that experiment on their own desks, with their own hands, and reached their own conclusion — which is a far more durable kind of persuasion than anything he could have printed. A thumb crushing a pill stayed the company's trademark for the next sixty years.

The business never rested on a single miracle compound. It rested on a better way to deliver almost any compound. Over the following decades the firm manufactured more than a hundred and eighty different medications in this new form. What began as a practical fix for a country practice became an industrial platform. The company expanded beyond pills into a broader pharmaceutical enterprise, shortened its name in nineteen-oh-two, grew into a multi-billion-dollar operation that helped define the modern drug industry, merged with Sweden's Pharmacia in nineteen ninety-five, and was bought by Pfizer in two thousand two. All of it the long echo of one insight: reliable delivery creates reliable markets.

Here's the unexpected consequence. Before friable pills, dosing was an art shadowed by doubt. After them, physicians could prescribe with confidence and patients could expect consistent effects. Mass production lowered costs and widened availability. Medicine moved from craft toward standardized product — and that shift is what made larger clinical trials, systematic pharmacology and the research-based pharmaceutical company possible at all. Upjohn's contribution wasn't a flashy molecule. It was infrastructure for every molecule that followed.

The same pattern still governs progress. Modern tablets, capsules and extended-release formulations all descend from the demand that a solid dose must dissolve when and where it's supposed to. Controlled-release coatings, multi-layer tablets and orally disintegrating films refine the original principle rather than replace it. And in biotech and digital health the parallel is hard to miss. Founders obsess over the active ingredient — the novel antibody, the gene therapy, the AI diagnostic — while underinvesting in the delivery system that makes the ingredient usable at scale. A brilliant compound that can't be dosed consistently is a laboratory curiosity. A reliable delivery platform turns curiosity into therapy, and therapy into industry.

Notice what Upjohn actually did. He attacked a constraint everyone else treated as fixed. The hard pill was accepted as the best available form; he treated it as a design failure. That posture — questioning the packaging rather than only the contents — shows up again and again in durable innovation, from mainframes giving way to personal devices to batch manufacturing giving way to continuous processes. The interface between the solution and its user is the neglected layer. Improve it and the underlying science suddenly gets far more powerful.

There's a quieter lesson about scale, too. Upjohn didn't stop at a better pill for his own patients. He built a machine, and then a company capable of producing that pill in volume at uniform quality. Most inventors stop at the prototype. The ones who reshape industries solve the production problem as well — and that's why his company outlived him by decades.

We're still wrestling with versions of the same problem. Drug shortages, counterfeit medicines, the challenge of getting advanced therapies into ordinary clinics — reliability of form, accuracy of dose, and the ability to manufacture at volume remain decisive. The technologies got more sophisticated. The requirement didn't change. Medicine only works when it reaches the patient in the right amount at the right time. Everything else is secondary.

So the story of the friable pill isn't really nostalgia for an old company. It's a recurring truth about where progress hides — in the unglamorous layer between discovery and use. Examine the delivery as carefully as the discovery. Treat consistency as a feature rather than an afterthought. Build the machinery that turns a good idea into a reliable product.

The market, and the patients, will notice.

Closing

So that was Episode forty-nine. We started with a weight-loss drug that's apparently been protecting people's lungs for years without anyone noticing, and a Chinese used-car market that's written off perfectly healthy electric vehicles because it can't read their batteries. We watched a salvage auction company pay nearly two billion dollars for an inspection business, and a bond desk in London buy Hungarian debt on a convergence bet that hasn't technically converged. We went to a small Yemeni port that just became leverage without firing a shot, and to a Shanghai laboratory whose cancer molecule is now GSK's to prove. We met a tiny American maker of atomic clocks having the quarter of its life because the world stopped trusting its borrowed reference signal, a Chinese tutoring company that found its first profit in an AI subscription, and a newsletter platform quietly paying podcasters two hundred million dollars a year with no attribution model at all. We finished twenty-five thousand years ago in Sulawesi, with two sets of teeth that had been telling us about human pharmacology the whole time, waiting for an instrument good enough to listen.

Then we walked into a week with a Fed that might hike, a Bank of Japan that probably will, a Bank of England whose vote count matters more than its decision, and two Nasdaq listings on Friday that are both, underneath, a bet on a model. The Knowledge Bomb went looking for the clock inside disruption, and found steamships that made sailing ships faster and banks still running COBOL fifty years after the microprocessor. Humor Me took the economic moat at its word and discovered that castles mostly don't get stormed — they get bypassed by somebody in a balloon. In the Greater Debate, J. Howard Pew and Richard Nixon spent an hour arguing about the price of bread and turned out to be arguing about time. And William Upjohn mailed pine boards to strangers, because he'd worked out that the gap between a good medicine and a working medicine was the whole business.

Every one of those was somebody mistaking the moment a thing became true for the moment the world would act on it.

Which is worth carrying into your own week. When somebody tells you what's going to win, they've answered the easy question. Ask them the hard one — how long, and what happens to everybody standing in between.

That's it for another episode of Wealth and Means — advice dressed up like hard work.

We hope you enjoyed the arc. From a battery nobody can read to a steamship that outlived its own obituary…a thumb crushing a pill…and a president freezing the price of bread. The pattern was simple: timing beats direction. Because first principles are rarely flashy…

Subscribe, rate, and share this episode. It helps more than you think.

We do this for you — to help you have a better week, a sharper mind, and maybe even a longer attention span.

And a special thanks to our sponsor AgentWeekly.ai

Until next time -- stay curious.

Stay kind.

And keep compounding.

Chapters